These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3230 related items for PubMed ID: 28566227

  • 1. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E, MOBIDIP study group.
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial.
    D2EFT Study Group.
    Lancet HIV; 2024 Jul; 11(7):e436-e448. PubMed ID: 38788744
    [Abstract] [Full Text] [Related]

  • 4. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM, OLE/RIS-EST13 Study Group.
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [Abstract] [Full Text] [Related]

  • 5. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ, GARDEL Study Group.
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [Abstract] [Full Text] [Related]

  • 6. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI, Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.
    Lancet Infect Dis; 2018 Jan; 18(1):47-57. PubMed ID: 29108797
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
    Eholie SP, Ekouevi DK, Chazallon C, Charpentier C, Messou E, Diallo Z, Zoungrana J, Minga A, Ngom Gueye NF, Hawerlander D, Dembele F, Colin G, Tchounga B, Karcher S, Le Carrou J, Tchabert-Guié A, Toni TD, Ouédraogo AS, Bado G, Toure Kane C, Seydi M, Poda A, Mensah E, Diallo I, Drabo YJ, Anglaret X, Brun-Vezinet F, FIT-2 study group.
    Lancet HIV; 2024 Jun; 11(6):e380-e388. PubMed ID: 38740027
    [Abstract] [Full Text] [Related]

  • 8. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
    Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.
    Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562
    [Abstract] [Full Text] [Related]

  • 9. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, A5288 Team.
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [Abstract] [Full Text] [Related]

  • 10. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM, Harrison LJ, Taiwo B, Wallis CL, Zheng L, Kim P, Kumarasamy N, Hosseinipour MC, Jarocki B, Mellors JW, Collier AC, ACTG A5273 Study Group.
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [Abstract] [Full Text] [Related]

  • 11. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S, GESIDA 7011 Study Group.
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
    Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A, NADIA Trial Team.
    Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
    [Abstract] [Full Text] [Related]

  • 13. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V, MONOD Study Group.
    BMC Med; 2017 Apr 24; 15(1):85. PubMed ID: 28434406
    [Abstract] [Full Text] [Related]

  • 14. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
    Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, Losso MH, Chetchotisakd P, Brites C, Sievers J, Brown D, Hopking J, Underwood M, Nascimento MC, Punekar Y, Gartland M, Smith K.
    Lancet Infect Dis; 2019 Mar 24; 19(3):253-264. PubMed ID: 30732940
    [Abstract] [Full Text] [Related]

  • 15. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.
    SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA.
    Lancet; 2013 Jun 15; 381(9883):2091-9. PubMed ID: 23769235
    [Abstract] [Full Text] [Related]

  • 16. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
    Venter WDF, Moorhouse M, Sokhela S, Serenata C, Akpomiemie G, Qavi A, Mashabane N, Arulappan N, Sim JW, Sinxadi PZ, Wiesner L, Maharaj E, Wallis C, Boyles T, Ripin D, Stacey S, Chitauri G, Hill A.
    Lancet HIV; 2019 Jul 15; 6(7):e428-e437. PubMed ID: 31202690
    [Abstract] [Full Text] [Related]

  • 17. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, DRIVE-FORWARD Study Group.
    Lancet HIV; 2018 May 15; 5(5):e211-e220. PubMed ID: 29592840
    [Abstract] [Full Text] [Related]

  • 18. Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression.
    Hung TC, Chen GJ, Cheng SH, Chen JH, Wei JL, Cheng CY, Hung CC.
    J Microbiol Immunol Infect; 2019 Dec 15; 52(6):865-871. PubMed ID: 31422059
    [Abstract] [Full Text] [Related]

  • 19. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA, SECOND-LINE study group.
    Lancet HIV; 2015 Feb 15; 2(2):e42-51. PubMed ID: 26424460
    [Abstract] [Full Text] [Related]

  • 20. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY, ARIA study team.
    Lancet HIV; 2017 Dec 15; 4(12):e536-e546. PubMed ID: 28729158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 162.